Study to understand how incretin mimetics affect cancer risk and attract experts to investigate these mechanisms, aiming to differentiate impacts on cancer risk from other health outcomes like weight loss or diabetes.
Funder: National Institutes of Health
Due Dates: January 7, 2027 (Closing date for applications)
Funding Amounts: No budget limit; requests must reflect project needs; up to 5 years; no cost sharing required
Summary: Supports preclinical and patient-based research on mechanisms through which incretin mimetics influence cancer risk.
Key Information: Well-developed projects need preliminary data; entirely in vitro studies and primarily epidemiologic projects are non-responsive.
The National Cancer Institute (NCI), part of NIH, supports investigator-initiated research examining how incretin mimetics influence cancer risk, rather than shorter-term outcomes such as weight loss or diabetes control. This R01 opportunity supports well-developed projects with preliminary data and accepts applications with or without clinical trials. It also seeks to attract scientists studying incretin mimetics in other diseases to cancer biology.
Research may examine immune, metabolic, hormonal, cytokine, or other signaling changes; cancer-specific effects; differences among population groups; or dose-dependent and off-target mechanisms. The announcement emphasizes GLP-1 and dual GLP-1/GIP-1 receptor agonists. Studies of other incretin mimetics must justify superior efficacy and/or a more favorable side-effect profile; administration route alone is insufficient justification. The central goal is to explain mechanisms of cancer prevention or promotion using biological samples from treated animals or humans.